News 2023-09-20
Porton Gets Improved in the 2023 S&P Global ESG Score
Porton Pharma Solutions Ltd. is glad to announce that it scored 38 (out of 100) in the 2023 S&P Global Corporate Sustainability Assessment reflecting an improvement of 9 points based on the 2023 methodology over the last year, where scores in all the three dimensions getting improved and exceeding the industry average. (CSA Score as of 25/08/2023).
Porton continues to gain ground in its environmental, social, and governance initiatives. In 2023, Porton establishes a top-down ESG governance structure, which includes Board Strategy and ESG Committee, ESG Executive Committee and ESG Working Team, to ensure the implementation of responsibilities and management measures. Meanwhile, Porton has identified 19 ESG high material issues and will further address and respond to these issues and enhance ESG performance.
|
Governance |
Social |
Environmental |
|
Business ethics Operational compliance |
R&D and innovation IP protection Product quality and safety Customer service Data and information security Digitalization Diversity, equity and inclusion Occupational health and safety Human capital development Supply chain security Access to healthcare and wellbeing Green chemistry Community communication and development |
Environmental policy and management systems Wastewater management Waste management Climate change |
For Porton, improving ESG governance and performance is a continuous evolutionary process. We will always be committed to cooperating with all stakeholders to achieve sustainable development.
Others
More
News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
News 2025-07-31
Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization
Overcoming the challenge of efficient synthesis of PKMYT1 inhibitor Lunresertib
